Advertisement

Ongoing Research in Cancer Immunotherapy for Children With Leukemia


Advertisement
Get Permission

THE CANCER IMMUNOTHERAPY PROGRAM at Children’s Hospital of Philadelphia has several clinical trials of chimeric antigen receptor (CAR) T-cell therapy available to eligible patients. 

Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy-Resistant or Refractory CD19-Positive Leukemia and Lymphoma 

Principal Investigator: Stephan A. Grupp, MD, PhD 

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19-Positive Leukemia and Lymphoma Previously Treated With Cell Therapy

Principal Investigator: Shannon L. Maude, MD, PhD 

Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia 

Principal Investigator: Stephan A. Grupp, MD, PhD 

Long-Term Follow-up of Patients Exposed to Lentiviral-Based CD19-Directed CAR T-Cell Therapy 

Principal Investigator: Stephan A. Grupp, MD, PhD 

Pilot Study of Autologous Anti-CD22 CAR-Redirected T Cells in Pediatric Patients With Chemotherapy-Resistant or Refractory Acute Lymphoblastic Leukemia 

Principal Investigator: Stephan A. Grupp, MD, PhD 

Phase II, Two-Cohort Study of Tocilizumab Optimization Timing for CTL019-Associated Cytokine-Release Syndrome Management in Pediatric Patients With CD19-Expressing Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia 

Principal Investigator: Stephan A. Grupp, MD, PhD 

For additional information on these and other trials for pediatric patients, visit Childrens Hospital of Philadelphia at www.chop.edu. ■


Related Articles

Pivotal CAR T-Cell Data Reported in Relapsed/Refractory B-Cell ALL

Stephan Grupp, MD, PhD

Stephan Grupp, MD, PhD

UPDATED RESULTS from the ELIANA clinical trial of CTL019 (tisagenlecleucel)—an investigational chimeric antigen receptor (CAR) T-cell therapy—found that remission rates are maintained at 6 months in relapsed/refractory pediatric and young adult patients with B-cell...

Advertisement

Advertisement



;
Advertisement